

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Proposed Single Technology Appraisal

## Galcanezumab for preventing migraine ID1372

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Eli Lilly (galcanezumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Brain and Spine Foundation</li> <li>• Migraine Action</li> <li>• Migraine Trust</li> <li>• Muslim Council of Britain</li> <li>• National Migraine Centre</li> <li>• Neurological Alliance</li> <li>• OUCH UK</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Brain Charity</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• British Association for the Study of Headache</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Pain Society</li> <li>• Institute of Neurology</li> <li>• Migraine in Primary Care Advisors</li> <li>• Neuromodulation Society of UK and Ireland</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• Neurological Alliance of Scotland</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Neurological Alliance</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (amitriptyline, propranolol, topiramate)</li> <li>• Allergan (botulinum toxin type A)</li> <li>• Aurobindo Pharma-Milpharm (topiramate)</li> <li>• Crescent Pharma (amitriptyline)</li> <li>• Genesis Pharmaceuticals (amitriptyline)</li> <li>• Glenmark Pharmaceuticals (topiramate)</li> <li>• Janssen-Cilag (topiramate)</li> <li>• Mylan (topiramate)</li> <li>• Novartis (erenumab)</li> </ul>

Provisional matrix for the proposed technology appraisal of galcanezumab for preventing migraine ID1372

Issue date: January 2019

© National Institute for Health and Care Excellence 2019. All rights reserved.

## Appendix C

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Central Manchester CCG</li> <li>• NHS England</li> <li>• NHS Wakefield CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Rosemont Pharmaceuticals (amitriptyline, propranolol)</li> <li>• Sandoz (propranolol)</li> <li>• Teva (amitriptyline, propranolol, topiramate)</li> <li>• Thame Laboratories (amitriptyline, propranolol)</li> <li>• Wockhardt (amitriptyline)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research Trust</li> <li>• British Neurological Research Trust</li> <li>• Cochrane Pain, Palliative Care and Supportive Care Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Hospital for Neurology and Neurosurgery</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.